National Institutes of Health: Rhabdomyosarcoma trials

The registry lists 43 Rhabdomyosarcoma studies with National Institutes of Health as lead sponsor. 1 are open to participants now and 27 have results posted.

Phase 1 14Phase 2 32Phase 3 1No phase 2(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• FGFR4 Chimeric Antigen Receptor (CAR) T Cells in Children and Young Adults With Recurrent or Refractory RhabdomyosarcomaRecruitingNCT06865664Phase 1
• Selpercatinib for the Treatment of Advanced Solid Tumors, Lymphomas, or Histiocytic Disorders With Activating RET Gene Alterations, a Pediatric MATCH Treatment TrialActive, not recruitingNCT04320888Phase 2Results posted
• Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment TrialActive, not recruitingNCT04284774Phase 2Results posted
• Ivosidenib in Treating Patients With Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With IDH1 Mutations (A Pediatric MATCH Treatment Trial)Active, not recruitingNCT04195555Phase 2Results posted
• Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)Active, not recruitingNCT03698994Phase 2Results posted
• Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)CompletedNCT03526250Phase 2Results posted
• Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)CompletedNCT03233204Phase 2Results posted
• Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)CompletedNCT03220035Phase 2Results posted
• Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)Active, not recruitingNCT03213704Phase 2Results posted
• Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)CompletedNCT03213678Phase 2Results posted
• Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)CompletedNCT03213665Phase 2Results posted
• Ensartinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With ALK or ROS1 Genomic Alterations (A Pediatric MATCH Treatment Trial)Active, not recruitingNCT03213652Phase 2Results posted
• Targeted Therapy Directed by Genetic Testing in Treating Pediatric Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphomas, or Histiocytic Disorders (The Pediatric MATCH Screening Trial)Active, not recruitingNCT03155620Phase 2Results posted
• Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar RhabdomyosarcomaTerminatedNCT03041701Phase 1/2Results posted
• Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare TumorsActive, not recruitingNCT02867592Phase 2Results posted
• Combination Chemotherapy With or Without Temsirolimus in Treating Patients With Intermediate Risk RhabdomyosarcomaActive, not recruitingNCT02567435Phase 3Results posted
• Nivolumab With or Without Ipilimumab in Treating Younger Patients With Recurrent or Refractory Solid Tumors or SarcomasCompletedNCT02304458Phase 1/2Results posted
• Adavosertib and Irinotecan Hydrochloride in Treating Younger Patients With Relapsed or Refractory Solid TumorsCompletedNCT02095132Phase 1/2Results posted
• Cixutumumab and Temsirolimus in Treating Younger Patients With Recurrent or Refractory SarcomaCompletedNCT01614795Phase 2Results posted
• Sorafenib Tosylate in Treating Younger Patients With Relapsed or Refractory Rhabdomyosarcoma, Wilms Tumor, Liver Cancer, or Thyroid CancerCompletedNCT01502410Phase 2Results posted
• Vinorelbine Tartrate and Cyclophosphamide in Combination With Bevacizumab or Temsirolimus in Treating Patients With Recurrent or Refractory RhabdomyosarcomaCompletedNCT01222715Phase 2Results posted
• Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic SarcomaCompletedNCT01154452Phase 1/2Results posted
• Temozolomide, Cixutumumab, and Combination Chemotherapy in Treating Patients With Metastatic RhabdomyosarcomaCompletedNCT01055314Phase 2Results posted
• Therapy to Treat Ewing's Sarcoma, Rhabdomyosarcoma or NeuroblastomaCompletedNCT00923351Phase 1/2Results posted
• Cixutumumab in Treating Patients With Relapsed or Refractory Solid TumorsCompletedNCT00831844Phase 2Results posted
• AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue SarcomaCompletedNCT00659360Phase 2Results posted
• Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue SarcomaCompletedNCT00112463Phase 2Results posted
• A Pilot Study of Autologous T-Cell Transplantation With Vaccine Driven Expansion of Anti-Tumor Effectors After Cytoreductive Therapy in Metastatic Pediatric SarcomasCompletedNCT00001566Phase 2Results posted
• Vincristine and Temozolomide in Combination With PEN-866 for Adolescents and Young Adults With Relapsed or Refractory Solid TumorsSuspendedNCT04890093Phase 1/2
• Cixutumumab and Doxorubicin Hydrochloride in Treating Patients With Unresectable, Locally Advanced, or Metastatic Soft Tissue SarcomaCompletedNCT00720174Phase 1
• HGS-ETR2 to Treat Children With Solid TumorsTerminatedNCT00428272Phase 1
• Ixabepilone in Treating Young Patients With Refractory Solid TumorsCompletedNCT00331643Phase 2
• Oxaliplatin and Irinotecan in Treating Young Patients With Refractory Solid Tumors or LymphomasCompletedNCT00101270Phase 1
• Tanespimycin in Treating Young Patients With Recurrent or Refractory Leukemia or Solid TumorsCompletedNCT00093821Phase 1
• Oxaliplatin in Treating Young Patients With Recurrent Solid Tumors That Have Not Responded to Previous TreatmentCompletedNCT00091182Phase 2
• Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid TumorsCompletedNCT00077454Phase 1
• Comparison of Chemotherapy Regimens in Treating Children With Relapsed or Progressive RhabdomyosarcomaCompletedNCT00025363Phase 2
• Flavopiridol in Treating Children With Relapsed or Refractory Solid Tumors or LymphomasCompletedNCT00012181Phase 1
• Comparison of Filgrastim and Filgrastim SD/01in Boosting White Cell Counts After Intensive ChemotherapyCompletedNCT00004853Phase 1
• Health-Related Outcomes in Patients Who Were Previously Treated for RhabdomyosarcomaCompletedNCT00003801Not applicable
• Evaluation, Treatment, and Natural History of Children and Young Adults With Cancer or Rare DiseasesCompletedNCT00001686
• A Pilot Study of Tumor-Specific Peptide Vaccination and IL-2 With or Without Autologous T Cell Transplantation in Recurrent Pediatric SarcomasCompletedNCT00001564Phase 2
• New Therapeutic Strategies for Patients With Ewing's Sarcoma Family of Tumors, High Risk Rhabdomyosarcoma, and NeuroblastomaCompletedNCT00001335Phase 2